Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative...

Area of Science:

• Hematology
• Cardiology
• Internal Medicine

Background:

• Cardiovascular (CV) risk factors in BCR::ABL1 negative chronic myeloproliferative neoplasms (MPNs) have an unclear prognostic role.
• MPN-related features often mask the impact of CV risk factors on thrombotic risk.
• Current MPN treatment strategies do not prioritize CV risk factor management, and treatment often mirrors general population guidelines despite MPN-specific nuances.

Purpose of the Study:

• To review the specific roles and management of individual CV risk factors in MPNs.
• To summarize recent advancements in understanding CV risk in MPN patients.
• To propose future research directions for optimizing CV risk management in MPNs.

Main Methods:

• Literature review focusing on individual cardiovascular risk factors in MPNs.
• Analysis of current treatment approaches for CV risk factors in the general population and MPN patients.
• Identification of knowledge gaps and areas for future research.

Main Results:

• The prognostic significance of CV risk factors in MPNs is not well-defined.
• Optimal management targets for metabolic factors (e.g., LDL, uric acid, HbA1c) in MPNs are undefined.
• Specificities of CV risk factors in MPNs require tailored management strategies.

Conclusions:

• Further research is needed to elucidate the prognostic role of CV risk factors in MPNs.
• Defining optimal management targets for metabolic derangements is crucial.
• Developing MPN-specific strategies for managing arterial hypertension, hyperlipidemia, chronic kidney disease, smoking, diabetes mellitus, hyperuricemia, obesity, and cachexia is essential for improving patient outcomes.